|
시장보고서
상품코드
2075766
발작성 야간 혈색소뇨증 치료제 시장 : 치료 접근별, 용도별, 유통 채널별, 지역별Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Therapeutic Approach, By Application, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
발작성 야간 혈색소뇨증 치료제 시장은 2026년에 13억 4,000만 달러로 추정되며, 2033년까지 26억 달러에 이를 전망입니다. 2026-2033년 CAGR 11.7%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 13억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 11.70% | 시장 규모 예측(2033년) : | 26억 달러 |
세계의 발작성 야간 혈색소뇨증(PNH) 치료제 시장은 보체 억제제, 유전자 치료, 단일클론 항체 등의 치료 접근법 범주로 구성되어 있으며, 재생불량성 빈혈에 동반된 PNH, 고전형 PNH, 무증상 PNH 등의 적응증에 대응하고 있습니다. 이러한 제품들은 병원 약국, 소매 약국, 온라인 약국 등의 분야에서 도입되어 효율성, 성능 및 신뢰성 향상에 기여하고 있습니다. 이러한 부문에서의 채용 확대와 지속적인 제품 혁신이 맞물려 시장 확대를 지속적으로 뒷받침하고 있습니다.
시장 역학 :
주요 적용 분야 수요 증가, 효율성과 성능에 대한 중요성 부각, 그리고 지속적인 제품 혁신이 전 세계 발작성 야간 혈색소뇨증 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 병원 약국 및 소매 약국에서의 채용 확대와 첨단 솔루션에 대한 투자 증가가 시장 확대를 더욱 뒷받침하고 있습니다.
예를 들어, 의료 서비스 제공업체들은 재생불량성 빈혈에 수반되는 PNH 및 관련 용도에 맞춘 제품 및 서비스를 점점 더 많이 개발하고 있습니다. 또한, 지속적인 연구 개발과 신기술의 통합을 통해 예측 기간 동안 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 세계 발작성 야간 혈색소뇨증 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 발작성 야간 혈색소뇨증 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 발작성 야간 헤모글로빈뇨증 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 발작성 야간 혈색소뇨증 치료제 시장 : 치료 접근별(2026-2033년)
제5장 발작성 야간 혈색소뇨증 치료제 시장 : 용도별(2026-2033년)
제6장 발작성 야간 혈색소뇨증 치료제 시장 : 유통 채널별(2026-2033년)
제7장 발작성 야간 혈색소뇨증 치료제 시장 : 지역별(2026-2033년)
제1장 경쟁 구도
제2장 섹션
AJY 26.07.09Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market is estimated to be valued at USD 1.34 billion in 2026 and is expected to reach USD 2.6 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.34 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.70% | 2033 Value Projection: | USD 2.6 billion |
The global paroxysmal nocturnal hemoglobinuria therapeutics market comprises therapeutic approach categories such as Complement Inhibitors, Gene Therapy, and Monoclonal Antibodies, serving applications including Aplastic Anemia Associated PNH, Classical PNH, and Subclinical PNH. These offerings are adopted across Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.
Market Dynamics:
Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global paroxysmal nocturnal hemoglobinuria therapeutics market. Expanding adoption among Hospital Pharmacy, and Retail Pharmacy and growing investment in advanced solutions are further supporting market expansion.
For instance, providers are increasingly developing offerings tailored to Aplastic Anemia Associated PNH and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global paroxysmal nocturnal hemoglobinuria therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Apellis Pharmaceuticals, Alexion Pharmaceuticals (AstraZeneca), Novartis AG, Roche Holding AG, Alnylam Pharmaceuticals, Sobi (Swedish Orphan Biovitrum), Sanofi, Biomarin Pharmaceutical Inc., Rigel Pharmaceuticals, Ikaria Holdings, Hemlibra (Roche), and Ionis Pharmaceuticals, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global paroxysmal nocturnal hemoglobinuria therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global paroxysmal nocturnal hemoglobinuria therapeutics market.
Detailed Segmentation:
- Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Therapeutic Approach (Revenue, USD Bn, 2021 - 2033)
- Complement Inhibitors
- Gene Therapy
- Monoclonal Antibodies
- Supportive Care
- Others
- Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Aplastic Anemia Associated PNH
- Classical PNH
- Subclinical PNH
- Others
- Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Apellis Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Alexion Pharmaceuticals (AstraZeneca)
- Novartis AG
- Roche Holding AG
- Alnylam Pharmaceuticals
- Sobi (Swedish Orphan Biovitrum)
- Sanofi
- Biomarin Pharmaceutical Inc.
- Rigel Pharmaceuticals
- Ikaria Holdings
- Hemlibra (Roche)
- Ionis Pharmaceuticals
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutic Approach
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Therapeutic Approach, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Complement Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Application, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Aplastic Anemia Associated PNH
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Classical PNH
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Subclinical PNH
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Distribution Channel, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Apellis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alexion Pharmaceuticals (AstraZeneca)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sobi (Swedish Orphan Biovitrum)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biomarin Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Rigel Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ikaria Holdings
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hemlibra (Roche)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
